Vivacitas Oncology, Inc. and IAG to Present at SNO 2021

Vivacitas Oncology, Inc. and IAG to Present at SNO 2021

Vivacitas Oncology, Inc. and IAG to Present at SNO 2021

Walnut Creek, CA, USA, and London, UK, November 18, 2021, Vivacitas Oncology, a privately-held oncology company focused on tough–to–treat cancers, and Image Analysis Group (IAG), a premier image analysis company and developer of the proprietary Artificial Intelligence (AI)-assisted Dynamika™ platform will present a poster at this year’s annual Society of Neuro-Oncology (SNO) conference November 18-21, 2021 in Boston, MA.

The poster “RESPONSE EVALUATION OF AR-67 FROM A PHASE-2 RECURRENT GLIOBLASTOMA TRIAL BY ARTIFICIAL INTELLIGENCE-ASSISTED TUMOR VOLUMETRIC ESTIMATION: COMPARISON WITH THE SUM OF THE PERPENDICULAR DIAMETERS PRODUCTS,” describes how using the Dynamika™ platform to analyze MRI images via novel AIassisted volumetric measurements may provide a more accurate estimation of patient responses to therapeutic interventions, potentially reducing the risk of drawing conclusions based on false positive or negative data.

The poster presentation will focus on comparing current standard of care and analytical approaches such as the Modified Radiographic Response Assessment in Neuro-Oncology (mRANO) in calculating the Sum of Perpendicular Diameters Products (SPDP) of tumor images and IAG’s AI-assisted Dynamika™ platform in estimating response rates to AR-67, Vivacitas’ lead investigational compound, in a patient subset from a Phase 2 clinical trial in recurrent Glioblastoma Multiforme (reGBM).

“We are excited about learning more about AR-67’s therapeutic potential in reGBM through our collaboration with IAG and application of their AI-assisted volumetric measurement platform”, said Tina Runk, EVP of Clinical Operations, Co-Founder, and Director of Vivacitas.

Dr. Diana Dupont-Roettger, the Chief Scientific Alliance Officer at IAG stated, “We are excited to bring the latest and most impactful imaging strategies to Vivacitas to ensure a scientific excellence and efficient drug development process.”

Details of the abstract and poster session are as follows:

Abstract # CTNI-45.

Title: Response Evaluation of AR-67 from a Phase 2 recurrent Glioblastoma Trial by Artificial Intelligence-assisted Tumor Volumetric Estimation: Comparison with the Sum of the Perpendicular Diameters Products.

Date: November 19, 2021 at 7:30 – 9:30 p.m. ET.

Location: Exhibit Hall D, Hynes Convention Center.

Presenter: Elise Brownell, PhD, EVP Portfolio and Project Management, Vivacitas Oncology, Inc., Walnut Creek, CA.

About Vivacitas Oncology, Inc.

Vivacitas Oncology is a private clinical stage biopharmaceutical company focused on tough-to-treat cancers. It originated with the vision of Dr. Joseph Rubinfeld (co-founder of Amgen) and Infusion 51a, LP to transform select chemotherapies beyond their initial potency, toxicity, stability and/or pharmacokinetics challenges and unlock maximum treatment and tolerability potential. Through an enduring spirit, Vivacitas continues to apply clarity, tenacity and vision in our fight against aggressive cancers and our pursuit of new treatment options for patients and their families worldwide. For further information please visit or reach out to

About IAG, Image Analysis Group

IAG, Image Analysis Group is unique partner to life sciences companies. We leverage our core expertise in medical image analysis in drug development and power of our cloud platform Dynamika™.  We support investors and biotech executive teams with deploying strategies for early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations. Thus, lowering the investment risks into advanced therapies while helping to accelerate study outcomes. Our bio-partnering team takes a broader view on the assets’ development and helps to bring our R&D solutions, operational breadth, radiological expertise and deploy these via risk-sharing financing and partnership models.

Learn more:

Reach out:

Follow the Company: Linkedin